Compass Therapeutics Inc. (NASDAQ: CMPX) reported a net loss of $66.5 million, or $0.42 per share, for the full year 2025, compared with a $49.4 million loss ($0.36 per share) in 2024. Research and development expenses rose to $56.0 million, up 32% from $42.3 million in 2024, while general and administrative costs increased to $16.9 million, up 12% from $15.1 million. Cash and marketable securities stood at $209 million as of December 31 2025, an $82 million increase from $127 million a year earlier, extending the company’s runway into 2028.
The widening net loss reflects the company’s continued investment in its pipeline. R&D spending grew largely because of $7.7 million in manufacturing costs for the lead asset tovecimig and $5.9 million for CTX‑10726, while G&A costs were driven by $0.7 million in pre‑commercialization expenses and $0.5 million in advisory fees. These increases are consistent with the company’s strategy to accelerate development and prepare for eventual commercialization.
Compass highlighted progress in its pipeline, noting that tovecimig met the primary endpoint of overall response rate in its Phase 2/3 COMPANION‑002 study in biliary tract cancer and that CTX‑8371 showed strong activity in heavily pre‑treated patients. The company also reported manufacturing costs for CTX‑10726, underscoring its commitment to advancing multiple candidates.
"2025 marked a year of significant progress for Compass, highlighted by our lead asset tovecimig successfully meeting the primary endpoint of overall response rate in the COMPANION‑002 Phase 2/3 study in patients with biliary tract cancer. We are excited to report the results of the key secondary endpoints next month," said Thomas Schuetz, MD, PhD, Chief Executive Officer. "2026 is poised to be a defining year for Compass…our progress is bolstered by our strong financial position with $209 million of cash and marketable securities, providing runway into 2028," he added.
Investors responded positively to the results, citing the strong clinical data for tovecimig and the company’s robust cash position as key drivers of confidence in Compass’s future prospects.
The company’s financial position and pipeline progress provide a solid foundation for continued development, while the increased R&D and G&A expenses highlight the capital intensity of its growth strategy. The positive clinical milestone for tovecimig de‑risks the lead asset, and the extended cash runway supports ongoing trials and potential future commercialization. However, the higher operating costs and the inherent regulatory risks associated with drug development remain headwinds that the company must navigate as it moves toward regulatory submissions and market entry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.